Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Sage Therapeutic Com (SAGE)

Sage Therapeutic Com (SAGE)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 3,722,605
  • Shares Outstanding, K 51,818
  • Annual Sales, $ 90,270 K
  • Annual Income, $ -372,880 K
  • 60-Month Beta 2.32
  • Price/Sales 674.46
  • Price/Cash Flow N/A
  • Price/Book 3.50

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 17 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/19
See More
  • Average Estimate -3.62
  • Number of Estimates 14
  • High Estimate -3.15
  • Low Estimate -4.04
  • Prior Year -3.38
  • Growth Rate Est. (year over year) -7.10%

Price Performance

See More
Period Period Low Period High Performance
1-Month
68.75 +2.49%
on 01/23/20
79.00 -10.81%
on 01/10/20
-4.18 (-5.60%)
since 12/23/19
3-Month
56.50 +24.71%
on 12/05/19
155.33 -54.64%
on 11/29/19
-71.81 (-50.47%)
since 10/23/19
52-Week
56.50 +24.71%
on 12/05/19
193.56 -63.60%
on 07/12/19
-60.28 (-46.11%)
since 01/23/19

Most Recent Stories

More News
Clovis Oncology is Among the Companies in the Biotechnology Industry with the Best Relative Performance (CLVS , AKBA , SAGE , FPRX , AGIO )

Below are the top five companies in the Biotechnology industry as measured by relative performance. This analysis was compiled based on yesterday's trading activity as we search for stocks that have the...

AKBA : 8.57 (+3.00%)
CLVS : 9.21 (+0.77%)
SAGE : 70.46 (-1.92%)
Sage Therapeutic Rises 1.09% on Heavy Volume: Watch For Potential Pullback

Sage Therapeutic (NASDAQ:SAGE) traded in a range yesterday that spanned from a low of $75.76 to a high of $77.57. Yesterday, the shares gained 1.1%, which took the trading range above the 3-day high...

SAGE : 70.46 (-1.92%)
Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Sage Therapeutics, Inc. (NASDAQ: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain,...

SAGE : 70.46 (-1.92%)
Sage Therapeutics to Present at J.P. Morgan Healthcare Conference on Monday, January 13, 2020

Sage Therapeutics (NASDAQ: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, today...

JPM : 136.54 (-0.10%)
SAGE : 70.46 (-1.92%)
Sage Therapeutic is Among the Companies in the Biotechnology Industry with the Best Relative Performance (SAGE , PBYI , BLUE , ATRA , REGN )

Here are the top 5 stocks in the Biotechnology industry ranked by performance. We compiled the trading activity from yesterday and then analyzed the industry looking for stocks that were outperforming....

BLUE : 89.72 (-4.35%)
PBYI : 8.82 (-3.40%)
SAGE : 70.46 (-1.92%)
HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Sage Therapeutics, Inc. (SAGE) Investors With 100K+ Losses to Contact Its Attorneys, Securities Fraud Investigation Opened

Hagens Berman urges Sage Therapeutics, Inc. (NASDAQ: SAGE) investors who have suffered losses in excess of $100,000 on purchases prior to December 5, 2019 to submit their losses now to learn if they qualify...

SAGE : 70.46 (-1.92%)
Biotech Stock Roundup: ASH Data in Focus, Amgen Gets FDA Nod to Remicade Biosimilar

The biotech sector witnesses pipeline updates from the annual ASH meet.

GILD : 63.94 (+0.80%)
AMGN : 235.04 (-0.72%)
BLUE : 89.72 (-4.35%)
FATE : 24.84 (+1.18%)
VRTX : 233.91 (-0.30%)
REGN : 356.60 (-0.71%)
SAGE : 70.46 (-1.92%)
HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Sage Therapeutics, Inc. (SAGE) Investors With 100K+ Losses to Contact Its Attorneys, Securities Fraud Investigation Opened

Hagens Berman urges Sage Therapeutics, Inc. (NASDAQ: SAGE) investors who have suffered losses in excess of $100,000 on purchases prior to December 5, 2019 to submit their losses now to learn if they qualify...

SAGE : 70.46 (-1.92%)
Sage Therapeutics Announces Planned Progression of SAGE-718 to Phase 2 in Huntington's Disease and Presentations at the 2019 Annual Meeting of the American College of Neuropsychopharmacology (ACNP)

Sage Therapeutics (NASDAQ: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, today...

SAGE : 70.46 (-1.92%)
Sage Therapeutics (SAGE) in Focus: Stock Moves 7.1% Higher

Sage Therapeutics (SAGE) shares rose more than 7% in the last trading session, amid huge volumes.

IRWD : 12.83 (+1.58%)
SAGE : 70.46 (-1.92%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Trade SAGE with:

Business Summary

SAGE Therapeutics Inc. is a biopharmaceutical company developing and commercializing medicines to treat life-threatening central nervous system (CNS) disorders. The Company provides treatments for schizophrenia, major depressive disorder, pain, and traumatic brain injury conditions. Its initial product...

See More

Key Turning Points

2nd Resistance Point 74.25
1st Resistance Point 72.36
Last Price 70.46
1st Support Level 68.66
2nd Support Level 66.85

See More

52-Week High 193.56
Fibonacci 61.8% 141.20
Fibonacci 50% 125.03
Fibonacci 38.2% 108.86
Last Price 70.46
52-Week Low 56.50

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar